A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to test the safety, tolerability, and pharmacokinetics of the
investigational drug CY6463 compared with placebo in individuals who are aged 65 years or
older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.